全体要約
自己血漿療法は、筋骨格系の怪我、スポーツ傷害、外傷などの治療に使用され、皮膚潰瘍や美容手術にも広く利用されています。この市場は、痛みを伴わない治療法への需要の高まりにより拡大しています。2023年の市場規模は数百万米ドルと推定され、2030年までに成長が見込まれています。
医療機器市場は2023年に6030億米ドルと推定され、今後6年間で年平均成長率5%で成長する見込みです。高齢化社会の健康ニーズの増加、慢性疾患や感染症の増加、発展途上市場の拡大が市場を牽引しています。
関連する質問
Zimmer Biomet Inc., Terumo Corporation, AdiStem Ltd., Arthrex, Inc., Stryker Corporation, Cesca Therapeutics, Inc., Biotechnology Institute BTI, Dr. PRP America LLC, EmCyte Corporation, Vivostat A/S, Regen Lab SA, Royal Biologics, Exactech, Inc., Plateltex S.R.O.
ユーザーフレンドリーな治療手順の需要増加, 外科手術を必要としない効果的な治療の提供, 高齢者人口の増加による医療サービスの需要拡大
概要
この手順は、痛みを伴う手術を必要とせず、優れた効果的な治療を提供します。
自家調整プラズマ療法の世界市場は、2023年にXX米ドルの価値があると推定され、2030年までにXX米ドルに再調整されると予測されており、2024年から2030年の予測期間中にCAGR %となる見込みです。
我々の調査によると、2023年の医療機器の世界市場は6030億米ドルと推定されており、今後6年間で年平均成長率（CAGR）は5%で成長する見込みです。世界の医療費支出は世界のGDPの10%を占めており、近年高齢化による健康ニーズの増加、慢性疾患や感染症の有病率の増加、新興市場の拡大により継続的に上昇しています。医療機器市場は医療業界において重要な役割を果たしています。この市場は、世界的な高度な医療サービスに対する需要の増加、医療技術の進歩、高齢者人口の増加、医療費の増加、早期の疾病診断と治療に関する意識の高まりなど、いくつかの要因によって推進されています。
報告の範囲
この報告書は、自己調整血漿療法の世界市場について、総売上高、主要企業の市場シェアとランキング、地域や国別、タイプ別、アプリケーション別の自己調整血漿療法の分析を重点的に提供することを目的としています。
自己調整血漿療法市場の規模、推定、および予測は、2023年を基準年として、2019年から2030年までの期間の歴史的データと予測データを考慮し、売上高（百万ドル）で提供されます。定量的および定性的分析を通じて、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自らの位置を分析し、自己調整血漿療法に関する情報に基づいたビジネス判断を下すのを助けます。
市場セグメンテーション
会社別
ジマー・バイオメット社
テルモ株式会社
アディステム株式会社
アースレックス株式会社
ストライカー社
セスカ・セラピューティクス社
バイオテクノロジー研究所 BTI
ドクターPRPアメリカLLC
エムサイト株式会社
Vivostat A/S
レジェンラボ株式会社
ロイヤルバイオロジクス
エクザクテック社
プラテルテックスS.R.O.
タイプ別セグメント：
純粋な血小板富血漿 (P-PRP)
白血球および血小板が豊富な血漿 (LPRP)
純粋血小板濃厚フィブリン（P-PRF）
白血球および血小板濃縮フィブリン (L-PRF)
用途別セグメント
病院
専門クリニック
外来手術センター
整形外科および外傷センター
研究機関
地域別
北アメリカ
アメリカ合衆国
カナダ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
アジア太平洋
中国
日本
韓国
中国 台湾
東南アジア
インド
ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
中東およびアフリカ
トルコ
サウジアラビア
UAE (アラブ首長国連邦)
章のアウトライン
第1章：レポートの範囲、世界の総市場規模を紹介します。この章では、市場の動態や市場の最新の発展、駆動要因と制約要因、業界の製造者が直面する課題とリスク、業界に関連する政策の分析も提供します。
第2章：自家調整プラズマ療法の製造業者の競合状況、収益市場シェア、最新の開発計画、合併および買収情報などの詳細分析です。
第3章：タイプ別のさまざまな市場セグメントの分析を提供し、各市場セグメントの市場規模と成長可能性をカバーします。これにより、読者が異なる市場セグメントにおけるブルーオーシャン市場を見つける手助けをします。
第4章：アプリケーション別のさまざまな市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーして、読者が異なる下流市場でブルーオーシャン市場を見つけるのを支援します。
第5章：地域レベルにおける自己条件付きプラズマ療法の収益です。各地域の市場規模と発展可能性の定量分析を提供し、各国の市場発展、将来の発展見通し、市場のスペース、および市場規模を紹介します。
第6章：国別の自己調整プラズマ療法の収益です。各国/地域のタイプ別および用途別のシグマデータを提供。
第7章：主要なプレイヤーのプロフィールを提供し、市場の主要企業の基本的な状況を詳細に紹介します。これには、製品収益、粗利、製品紹介、最近の開発などが含まれます。
第8章: 業界の上下流を含む産業チェーンの分析です。
第9章: 結論。
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 市場概要
1.1 自己血漿療法 : プロダクトのイントロダクション
1.2 グローバルの市場規模、市場予測
1.3 自己血漿療法市場トレンドと成長ドライバー
1.3.1 自己血漿療法業界トレンド
1.3.2 自己血漿療法市場のドライバーと事業機会
1.3.3 自己血漿療法市場の課題
1.3.4 自己血漿療法市場の抑制要因
1.4 前提条件と限界
1.5 調査の目的
1.6 対象年
2 競合分析、企業別
2.1 グローバルの自己血漿療法、プレイヤー収益ランキング（2023年）
2.2 グローバルにおける自己血漿療法市場の収益規模、企業別（2019年～2024年）
2.3 自己血漿療法の主要企業、製造・販売拠点およびヘッドクオーター
2.4 自己血漿療法の主要企業、製品展開
2.5 自己血漿療法の主要企業、量産開始時期
2.6 自己血漿療法市場の競争状況分析
2.6.1 自己血漿療法市場集中度比率（2019年～2024年）
2.6.2 グローバルの自己血漿療法、上位企業5～10社の収益（2023年）
2.6.3 グローバルの自己血漿療法、Tier別上位企業（Tier 1、Tier 2、Tier 3）、2023年の収益ベース
2.7 M&A、拡大
3 セグメンテーション、タイプ別
3.1 イントロダクション、タイプ別
3.1.1 多血小板血漿(P-PRP)
3.1.2 白血球・多血小板血漿(LPRP)
3.1.3 純血小板リッチフィブリン(P-PRF)
3.1.4 白血球・血小板リッチフィブリン(L-PRF)
3.2 グローバルの自己血漿療法の売上規模、金額ベース、タイプ別
3.2.1 グローバルの自己血漿療法の売上規模、金額ベース、タイプ別（2019年、2023年、2030年）
3.2.2 グローバルの自己血漿療法の売上規模、金額ベース、タイプ別（2019年～2030年）
3.2.3 グローバルの自己血漿療法の売上規模、金額ベース、タイプ別（%）（2019年～2030年）
4 セグメンテーション、用途別
4.1 イントロダクション、用途別
4.1.1 病院
4.1.2 専門クリニック
4.1.3 外来手術センター
4.1.4 整形外科と外傷センター
4.1.5 研究機関
4.2 グローバルの自己血漿療法の売上規模、金額ベース、用途別
4.2.1 グローバルの自己血漿療法の売上規模、金額ベース、用途別（2019年、2023年、2030年）
4.2.2 グローバルの自己血漿療法の売上規模、金額ベース、用途別（2019年～2030年）
4.2.3 グローバルの自己血漿療法の売上規模、金額ベース、用途別（%）（2019年～2030年）
5 セグメンテーション、地域別
5.1 グローバルの自己血漿療法の売上規模、金額ベース、地域別
5.2 北米
5.2.1 北米の自己血漿療法売上規模、金額ベース、2019年～2030年
5.2.2 北米の自己血漿療法の売上規模、金額ベース、国別（%）、2023年、2030年
5.3 ヨーロッパ
5.3.1 ヨーロッパの自己血漿療法売上規模、金額ベース、2019年～2030年
5.3.2 ヨーロッパの自己血漿療法の売上規模、金額ベース、国別（%）、2023年、2030年
5.4 アジア太平洋
5.4.1 アジア太平洋の自己血漿療法売上規模、金額ベース、2019年～2030年
5.4.2 アジア太平洋の自己血漿療法の売上規模、金額ベース、国別（%）、2023年、2030年
5.5 南米
5.5.1 南米の自己血漿療法売上規模、金額ベース、2019年～2030年
5.5.2 南米の自己血漿療法の売上規模、金額ベース、国別（%）、2023年、2030年
5.6 中東・アフリカ
5.6.1 中東・アフリカの自己血漿療法売上規模、金額ベース、2019年～2030年
5.6.2 中東・アフリカの自己血漿療法の売上規模、金額ベース、国別（%）、2023年、2030年
6 主要国・地域によるセグメンテーション
6.1 主要国・地域の自己血漿療法の売上成長トレンド、金額ベース（2019年、2023年、2030年）
6.2 主要国・地域の自己血漿療法の売上、金額ベース
6.3 米国
6.4 ヨーロッパ
6.5 中国
6.6 日本
6.7 韓国
6.8 東南アジア
6.9 インド
7 企業プロファイル
7.1 Zimmer Biomet Inc
7.2 Terumo Corporation
7.2.1 Terumo Corporation : プロファイル
7.2.2 Terumo Corporation : 主な事業
7.2.3 Terumo Corporation : 自己血漿療法の製品、サービス、ソリューション
7.2.4 Terumo Corporation : 自己血漿療法の収益（百万米ドル）（2019年～2024年）
7.2.5 Terumo Corporation：近況
7.3 AdiStem Ltd
7.4 Arthrex, Inc
7.5 Stryker Corporation
7.5.1 Stryker Corporation : プロファイル
7.5.2 Stryker Corporation : 主な事業
7.5.3 Stryker Corporation : 自己血漿療法の製品、サービス、ソリューション
7.5.4 Stryker Corporation : 自己血漿療法の収益（百万米ドル）（2019年～2024年）
7.5.5 Stryker Corporation：近況
7.6 Cesca Therapeutics, Inc
7.7 Biotechnology Institute BTI
7.7.1 Biotechnology Institute BTI : プロファイル
7.7.2 Biotechnology Institute BTI : 主な事業
7.7.3 Biotechnology Institute BTI : 自己血漿療法の製品、サービス、ソリューション
7.7.4 Biotechnology Institute BTI : 自己血漿療法の収益（百万米ドル）（2019年～2024年）
7.7.5 Biotechnology Institute BTI：近況
7.8 Dr\. PRP America LLC
7.8.1 Dr\. PRP America LLC : プロファイル
7.8.2 Dr\. PRP America LLC : 主な事業
7.8.3 Dr\. PRP America LLC : 自己血漿療法の製品、サービス、ソリューション
7.8.4 Dr\. PRP America LLC : 自己血漿療法の収益（百万米ドル）（2019年～2024年）
7.8.5 Dr\. PRP America LLC：近況
7.9 EmCyte Corporation
7.9.1 EmCyte Corporation : プロファイル
7.9.2 EmCyte Corporation : 主な事業
7.9.3 EmCyte Corporation : 自己血漿療法の製品、サービス、ソリューション
7.9.4 EmCyte Corporation : 自己血漿療法の収益（百万米ドル）（2019年～2024年）
7.9.5 EmCyte Corporation：近況
7.10 Vivostat A/S
7.10.1 Vivostat A/S : プロファイル
7.10.2 Vivostat A/S : 主な事業
7.10.3 Vivostat A/S : 自己血漿療法の製品、サービス、ソリューション
7.10.4 Vivostat A/S : 自己血漿療法の収益（百万米ドル）（2019年～2024年）
7.10.5 Vivostat A/S：近況
7.11 Regen Lab SA
7.11.1 Regen Lab SA : プロファイル
7.11.2 Regen Lab SA : 主な事業
7.11.3 Regen Lab SA : 自己血漿療法の製品、サービス、ソリューション
7.11.4 Regen Lab SA : 自己血漿療法の収益（百万米ドル）（2019年～2024年）
7.11.5 Regen Lab SA：近況
7.12 Royal Biologics
7.12.1 Royal Biologics : プロファイル
7.12.2 Royal Biologics : 主な事業
7.12.3 Royal Biologics : 自己血漿療法の製品、サービス、ソリューション
7.12.4 Royal Biologics : 自己血漿療法の収益（百万米ドル）（2019年～2024年）
7.12.5 Royal Biologics：近況
7.13 Exactech, Inc
7.14 Plateltex S\.R\.O
8 業界チェーン分析
8.1 自己血漿療法業界バリューチェーン
8.2 自己血漿療法市場の上流分析
8.2.1 主要原材料
8.2.2 原材料と主要サプライヤー
8.2.3 製造コスト構造
8.3 中流分析
8.4 下流分析（顧客についての分析）
8.5 営業販売モデル、販売チャネル
8.5.1 自己血漿療法 営業販売モデル
8.5.2 販売チャネル
8.5.3 自己血漿療法の流通業者
9 調査の結果・結論
10 付録
10.1 調査手法
10.1.1 調査手法 / 調査アプローチ
10.1.2 データソース
10.2 執筆者の詳細
10.3 免責事項
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
This procedure provides excellent and effective treatment without the need for painful surgery.
The global market for Autologous Conditioned Plasma Therapy was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Autologous Conditioned Plasma Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Autologous Conditioned Plasma Therapy by region & country, by Type, and by Application.
The Autologous Conditioned Plasma Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Autologous Conditioned Plasma Therapy.
Market Segmentation
By Company
Zimmer Biomet Inc.
Terumo Corporation
AdiStem Ltd.
Arthrex, Inc.
Stryker Corporation
Cesca Therapeutics, Inc.
Biotechnology Institute BTI
Dr. PRP America LLC
EmCyte Corporation
Vivostat A/S
Regen Lab SA
Royal Biologics
Exactech, Inc.
Plateltex S.R.O.
Segment by Type:
Pure Platelet-Rich Plasma (P-PRP)
Leukocyte- and Platelet-Rich Plasma (LPRP)
Pure Platelet-Rich Fibrin (P-PRF)
Leukocyte- and Platelet-Rich Fibrin (L-PRF)
Segment by Application
Hospitals
Specialized Clinics
Ambulatory Surgical Centers
Orthopedic & Trauma Centers
Research Institutes
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Autologous Conditioned Plasma Therapy manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Autologous Conditioned Plasma Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Autologous Conditioned Plasma Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Autologous Conditioned Plasma Therapy Product Introduction
1.2 Global Autologous Conditioned Plasma Therapy Market Size Forecast
1.3 Autologous Conditioned Plasma Therapy Market Trends & Drivers
1.3.1 Autologous Conditioned Plasma Therapy Industry Trends
1.3.2 Autologous Conditioned Plasma Therapy Market Drivers & Opportunity
1.3.3 Autologous Conditioned Plasma Therapy Market Challenges
1.3.4 Autologous Conditioned Plasma Therapy Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Autologous Conditioned Plasma Therapy Players Revenue Ranking (2023)
2.2 Global Autologous Conditioned Plasma Therapy Revenue by Company (2019-2024)
2.3 Key Companies Autologous Conditioned Plasma Therapy Manufacturing Base Distribution and Headquarters
2.4 Key Companies Autologous Conditioned Plasma Therapy Product Offered
2.5 Key Companies Time to Begin Mass Production of Autologous Conditioned Plasma Therapy
2.6 Autologous Conditioned Plasma Therapy Market Competitive Analysis
2.6.1 Autologous Conditioned Plasma Therapy Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Autologous Conditioned Plasma Therapy Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Autologous Conditioned Plasma Therapy as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Pure Platelet-Rich Plasma (P-PRP)
3.1.2 Leukocyte- and Platelet-Rich Plasma (LPRP)
3.1.3 Pure Platelet-Rich Fibrin (P-PRF)
3.1.4 Leukocyte- and Platelet-Rich Fibrin (L-PRF)
3.2 Global Autologous Conditioned Plasma Therapy Sales Value by Type
3.2.1 Global Autologous Conditioned Plasma Therapy Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Autologous Conditioned Plasma Therapy Sales Value, by Type (2019-2030)
3.2.3 Global Autologous Conditioned Plasma Therapy Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Specialized Clinics
4.1.3 Ambulatory Surgical Centers
4.1.4 Orthopedic & Trauma Centers
4.1.5 Research Institutes
4.2 Global Autologous Conditioned Plasma Therapy Sales Value by Application
4.2.1 Global Autologous Conditioned Plasma Therapy Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Autologous Conditioned Plasma Therapy Sales Value, by Application (2019-2030)
4.2.3 Global Autologous Conditioned Plasma Therapy Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Autologous Conditioned Plasma Therapy Sales Value by Region
5.1.1 Global Autologous Conditioned Plasma Therapy Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Autologous Conditioned Plasma Therapy Sales Value by Region (2019-2024)
5.1.3 Global Autologous Conditioned Plasma Therapy Sales Value by Region (2025-2030)
5.1.4 Global Autologous Conditioned Plasma Therapy Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Autologous Conditioned Plasma Therapy Sales Value, 2019-2030
5.2.2 North America Autologous Conditioned Plasma Therapy Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Autologous Conditioned Plasma Therapy Sales Value, 2019-2030
5.3.2 Europe Autologous Conditioned Plasma Therapy Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Autologous Conditioned Plasma Therapy Sales Value, 2019-2030
5.4.2 Asia Pacific Autologous Conditioned Plasma Therapy Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Autologous Conditioned Plasma Therapy Sales Value, 2019-2030
5.5.2 South America Autologous Conditioned Plasma Therapy Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Autologous Conditioned Plasma Therapy Sales Value, 2019-2030
5.6.2 Middle East & Africa Autologous Conditioned Plasma Therapy Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Autologous Conditioned Plasma Therapy Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Autologous Conditioned Plasma Therapy Sales Value
6.3 United States
6.3.1 United States Autologous Conditioned Plasma Therapy Sales Value, 2019-2030
6.3.2 United States Autologous Conditioned Plasma Therapy Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Autologous Conditioned Plasma Therapy Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Autologous Conditioned Plasma Therapy Sales Value, 2019-2030
6.4.2 Europe Autologous Conditioned Plasma Therapy Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Autologous Conditioned Plasma Therapy Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Autologous Conditioned Plasma Therapy Sales Value, 2019-2030
6.5.2 China Autologous Conditioned Plasma Therapy Sales Value by Type (%), 2023 VS 2030
6.5.3 China Autologous Conditioned Plasma Therapy Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Autologous Conditioned Plasma Therapy Sales Value, 2019-2030
6.6.2 Japan Autologous Conditioned Plasma Therapy Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Autologous Conditioned Plasma Therapy Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Autologous Conditioned Plasma Therapy Sales Value, 2019-2030
6.7.2 South Korea Autologous Conditioned Plasma Therapy Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Autologous Conditioned Plasma Therapy Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Autologous Conditioned Plasma Therapy Sales Value, 2019-2030
6.8.2 Southeast Asia Autologous Conditioned Plasma Therapy Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Autologous Conditioned Plasma Therapy Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Autologous Conditioned Plasma Therapy Sales Value, 2019-2030
6.9.2 India Autologous Conditioned Plasma Therapy Sales Value by Type (%), 2023 VS 2030
6.9.3 India Autologous Conditioned Plasma Therapy Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Zimmer Biomet Inc.
7.1.1 Zimmer Biomet Inc. Profile
7.1.2 Zimmer Biomet Inc. Main Business
7.1.3 Zimmer Biomet Inc. Autologous Conditioned Plasma Therapy Products, Services and Solutions
7.1.4 Zimmer Biomet Inc. Autologous Conditioned Plasma Therapy Revenue (US$ Million) & (2019-2024)
7.1.5 Zimmer Biomet Inc. Recent Developments
7.2 Terumo Corporation
7.2.1 Terumo Corporation Profile
7.2.2 Terumo Corporation Main Business
7.2.3 Terumo Corporation Autologous Conditioned Plasma Therapy Products, Services and Solutions
7.2.4 Terumo Corporation Autologous Conditioned Plasma Therapy Revenue (US$ Million) & (2019-2024)
7.2.5 Terumo Corporation Recent Developments
7.3 AdiStem Ltd.
7.3.1 AdiStem Ltd. Profile
7.3.2 AdiStem Ltd. Main Business
7.3.3 AdiStem Ltd. Autologous Conditioned Plasma Therapy Products, Services and Solutions
7.3.4 AdiStem Ltd. Autologous Conditioned Plasma Therapy Revenue (US$ Million) & (2019-2024)
7.3.5 Arthrex, Inc. Recent Developments
7.4 Arthrex, Inc.
7.4.1 Arthrex, Inc. Profile
7.4.2 Arthrex, Inc. Main Business
7.4.3 Arthrex, Inc. Autologous Conditioned Plasma Therapy Products, Services and Solutions
7.4.4 Arthrex, Inc. Autologous Conditioned Plasma Therapy Revenue (US$ Million) & (2019-2024)
7.4.5 Arthrex, Inc. Recent Developments
7.5 Stryker Corporation
7.5.1 Stryker Corporation Profile
7.5.2 Stryker Corporation Main Business
7.5.3 Stryker Corporation Autologous Conditioned Plasma Therapy Products, Services and Solutions
7.5.4 Stryker Corporation Autologous Conditioned Plasma Therapy Revenue (US$ Million) & (2019-2024)
7.5.5 Stryker Corporation Recent Developments
7.6 Cesca Therapeutics, Inc.
7.6.1 Cesca Therapeutics, Inc. Profile
7.6.2 Cesca Therapeutics, Inc. Main Business
7.6.3 Cesca Therapeutics, Inc. Autologous Conditioned Plasma Therapy Products, Services and Solutions
7.6.4 Cesca Therapeutics, Inc. Autologous Conditioned Plasma Therapy Revenue (US$ Million) & (2019-2024)
7.6.5 Cesca Therapeutics, Inc. Recent Developments
7.7 Biotechnology Institute BTI
7.7.1 Biotechnology Institute BTI Profile
7.7.2 Biotechnology Institute BTI Main Business
7.7.3 Biotechnology Institute BTI Autologous Conditioned Plasma Therapy Products, Services and Solutions
7.7.4 Biotechnology Institute BTI Autologous Conditioned Plasma Therapy Revenue (US$ Million) & (2019-2024)
7.7.5 Biotechnology Institute BTI Recent Developments
7.8 Dr. PRP America LLC
7.8.1 Dr. PRP America LLC Profile
7.8.2 Dr. PRP America LLC Main Business
7.8.3 Dr. PRP America LLC Autologous Conditioned Plasma Therapy Products, Services and Solutions
7.8.4 Dr. PRP America LLC Autologous Conditioned Plasma Therapy Revenue (US$ Million) & (2019-2024)
7.8.5 Dr. PRP America LLC Recent Developments
7.9 EmCyte Corporation
7.9.1 EmCyte Corporation Profile
7.9.2 EmCyte Corporation Main Business
7.9.3 EmCyte Corporation Autologous Conditioned Plasma Therapy Products, Services and Solutions
7.9.4 EmCyte Corporation Autologous Conditioned Plasma Therapy Revenue (US$ Million) & (2019-2024)
7.9.5 EmCyte Corporation Recent Developments
7.10 Vivostat A/S
7.10.1 Vivostat A/S Profile
7.10.2 Vivostat A/S Main Business
7.10.3 Vivostat A/S Autologous Conditioned Plasma Therapy Products, Services and Solutions
7.10.4 Vivostat A/S Autologous Conditioned Plasma Therapy Revenue (US$ Million) & (2019-2024)
7.10.5 Vivostat A/S Recent Developments
7.11 Regen Lab SA
7.11.1 Regen Lab SA Profile
7.11.2 Regen Lab SA Main Business
7.11.3 Regen Lab SA Autologous Conditioned Plasma Therapy Products, Services and Solutions
7.11.4 Regen Lab SA Autologous Conditioned Plasma Therapy Revenue (US$ Million) & (2019-2024)
7.11.5 Regen Lab SA Recent Developments
7.12 Royal Biologics
7.12.1 Royal Biologics Profile
7.12.2 Royal Biologics Main Business
7.12.3 Royal Biologics Autologous Conditioned Plasma Therapy Products, Services and Solutions
7.12.4 Royal Biologics Autologous Conditioned Plasma Therapy Revenue (US$ Million) & (2019-2024)
7.12.5 Royal Biologics Recent Developments
7.13 Exactech, Inc.
7.13.1 Exactech, Inc. Profile
7.13.2 Exactech, Inc. Main Business
7.13.3 Exactech, Inc. Autologous Conditioned Plasma Therapy Products, Services and Solutions
7.13.4 Exactech, Inc. Autologous Conditioned Plasma Therapy Revenue (US$ Million) & (2019-2024)
7.13.5 Exactech, Inc. Recent Developments
7.14 Plateltex S.R.O.
7.14.1 Plateltex S.R.O. Profile
7.14.2 Plateltex S.R.O. Main Business
7.14.3 Plateltex S.R.O. Autologous Conditioned Plasma Therapy Products, Services and Solutions
7.14.4 Plateltex S.R.O. Autologous Conditioned Plasma Therapy Revenue (US$ Million) & (2019-2024)
7.14.5 Plateltex S.R.O. Recent Developments
8 Industry Chain Analysis
8.1 Autologous Conditioned Plasma Therapy Industrial Chain
8.2 Autologous Conditioned Plasma Therapy Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Autologous Conditioned Plasma Therapy Sales Model
8.5.2 Sales Channel
8.5.3 Autologous Conditioned Plasma Therapy Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables Table 1. Autologous Conditioned Plasma Therapy Market Trends Table 2. Autologous Conditioned Plasma Therapy Market Drivers & Opportunity Table 3. Autologous Conditioned Plasma Therapy Market Challenges Table 4. Autologous Conditioned Plasma Therapy Market Restraints Table 5. Global Autologous Conditioned Plasma Therapy Revenue by Company (2019-2024) & (US$ Million) Table 6. Global Autologous Conditioned Plasma Therapy Revenue Market Share by Company (2019-2024) Table 7. Key Companies Autologous Conditioned Plasma Therapy Manufacturing Base Distribution and Headquarters Table 8. Key Companies Autologous Conditioned Plasma Therapy Product Type Table 9. Key Companies Time to Begin Mass Production of Autologous Conditioned Plasma Therapy Table 10. Global Autologous Conditioned Plasma Therapy Companies Market Concentration Ratio (CR5 and HHI) Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Autologous Conditioned Plasma Therapy as of 2023) Table 12. Mergers & Acquisitions, Expansion Plans Table 13. Global Autologous Conditioned Plasma Therapy Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million) Table 14. Global Autologous Conditioned Plasma Therapy Sales Value by Type (2019-2024) & (US$ Million) Table 15. Global Autologous Conditioned Plasma Therapy Sales Value by Type (2025-2030) & (US$ Million) Table 16. Global Autologous Conditioned Plasma Therapy Sales Market Share in Value by Type (2019-2024) & (%) Table 17. Global Autologous Conditioned Plasma Therapy Sales Market Share in Value by Type (2025-2030) & (%) Table 18. Global Autologous Conditioned Plasma Therapy Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million) Table 19. Global Autologous Conditioned Plasma Therapy Sales Value by Application (2019-2024) & (US$ Million) Table 20. Global Autologous Conditioned Plasma Therapy Sales Value by Application (2025-2030) & (US$ Million) Table 21. Global Autologous Conditioned Plasma Therapy Sales Market Share in Value by Application (2019-2024) & (%) Table 22. Global Autologous Conditioned Plasma Therapy Sales Market Share in Value by Application (2025-2030) & (%) Table 23. Global Autologous Conditioned Plasma Therapy Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million) Table 24. Global Autologous Conditioned Plasma Therapy Sales Value by Region (2019-2024) & (US$ Million) Table 25. Global Autologous Conditioned Plasma Therapy Sales Value by Region (2025-2030) & (US$ Million) Table 26. Global Autologous Conditioned Plasma Therapy Sales Value by Region (2019-2024) & (%) Table 27. Global Autologous Conditioned Plasma Therapy Sales Value by Region (2025-2030) & (%) Table 28. Key Countries/Regions Autologous Conditioned Plasma Therapy Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030 Table 29. Key Countries/Regions Autologous Conditioned Plasma Therapy Sales Value, (2019-2024) & (US$ Million) Table 30. Key Countries/Regions Autologous Conditioned Plasma Therapy Sales Value, (2025-2030) & (US$ Million) Table 31. Zimmer Biomet Inc. Basic Information List Table 32. Zimmer Biomet Inc. Description and Business Overview Table 33. Zimmer Biomet Inc. Autologous Conditioned Plasma Therapy Products, Services and Solutions Table 34. Revenue (US$ Million) in Autologous Conditioned Plasma Therapy Business of Zimmer Biomet Inc. (2019-2024) Table 35. Zimmer Biomet Inc. Recent Developments Table 36. Terumo Corporation Basic Information List Table 37. Terumo Corporation Description and Business Overview Table 38. Terumo Corporation Autologous Conditioned Plasma Therapy Products, Services and Solutions Table 39. Revenue (US$ Million) in Autologous Conditioned Plasma Therapy Business of Terumo Corporation (2019-2024) Table 40. Terumo Corporation Recent Developments Table 41. AdiStem Ltd. Basic Information List Table 42. AdiStem Ltd. Description and Business Overview Table 43. AdiStem Ltd. Autologous Conditioned Plasma Therapy Products, Services and Solutions Table 44. Revenue (US$ Million) in Autologous Conditioned Plasma Therapy Business of AdiStem Ltd. (2019-2024) Table 45. AdiStem Ltd. Recent Developments Table 46. Arthrex, Inc. Basic Information List Table 47. Arthrex, Inc. Description and Business Overview Table 48. Arthrex, Inc. Autologous Conditioned Plasma Therapy Products, Services and Solutions Table 49. Revenue (US$ Million) in Autologous Conditioned Plasma Therapy Business of Arthrex, Inc. (2019-2024) Table 50. Arthrex, Inc. Recent Developments Table 51. Stryker Corporation Basic Information List Table 52. Stryker Corporation Description and Business Overview Table 53. Stryker Corporation Autologous Conditioned Plasma Therapy Products, Services and Solutions Table 54. Revenue (US$ Million) in Autologous Conditioned Plasma Therapy Business of Stryker Corporation (2019-2024) Table 55. Stryker Corporation Recent Developments Table 56. Cesca Therapeutics, Inc. Basic Information List Table 57. Cesca Therapeutics, Inc. Description and Business Overview Table 58. Cesca Therapeutics, Inc. Autologous Conditioned Plasma Therapy Products, Services and Solutions Table 59. Revenue (US$ Million) in Autologous Conditioned Plasma Therapy Business of Cesca Therapeutics, Inc. (2019-2024) Table 60. Cesca Therapeutics, Inc. Recent Developments Table 61. Biotechnology Institute BTI Basic Information List Table 62. Biotechnology Institute BTI Description and Business Overview Table 63. Biotechnology Institute BTI Autologous Conditioned Plasma Therapy Products, Services and Solutions Table 64. Revenue (US$ Million) in Autologous Conditioned Plasma Therapy Business of Biotechnology Institute BTI (2019-2024) Table 65. Biotechnology Institute BTI Recent Developments Table 66. Dr. PRP America LLC Basic Information List Table 67. Dr. PRP America LLC Description and Business Overview Table 68. Dr. PRP America LLC Autologous Conditioned Plasma Therapy Products, Services and Solutions Table 69. Revenue (US$ Million) in Autologous Conditioned Plasma Therapy Business of Dr. PRP America LLC (2019-2024) Table 70. Dr. PRP America LLC Recent Developments Table 71. EmCyte Corporation Basic Information List Table 72. EmCyte Corporation Description and Business Overview Table 73. EmCyte Corporation Autologous Conditioned Plasma Therapy Products, Services and Solutions Table 74. Revenue (US$ Million) in Autologous Conditioned Plasma Therapy Business of EmCyte Corporation (2019-2024) Table 75. EmCyte Corporation Recent Developments Table 76. Vivostat A/S Basic Information List Table 77. Vivostat A/S Description and Business Overview Table 78. Vivostat A/S Autologous Conditioned Plasma Therapy Products, Services and Solutions Table 79. Revenue (US$ Million) in Autologous Conditioned Plasma Therapy Business of Vivostat A/S (2019-2024) Table 80. Vivostat A/S Recent Developments Table 81. Regen Lab SA Basic Information List Table 82. Regen Lab SA Description and Business Overview Table 83. Regen Lab SA Autologous Conditioned Plasma Therapy Products, Services and Solutions Table 84. Revenue (US$ Million) in Autologous Conditioned Plasma Therapy Business of Regen Lab SA (2019-2024) Table 85. Regen Lab SA Recent Developments Table 86. Royal Biologics Basic Information List Table 87. Royal Biologics Description and Business Overview Table 88. Royal Biologics Autologous Conditioned Plasma Therapy Products, Services and Solutions Table 89. Revenue (US$ Million) in Autologous Conditioned Plasma Therapy Business of Royal Biologics (2019-2024) Table 90. Royal Biologics Recent Developments Table 91. Exactech, Inc. Basic Information List Table 92. Exactech, Inc. Description and Business Overview Table 93. Exactech, Inc. Autologous Conditioned Plasma Therapy Products, Services and Solutions Table 94. Revenue (US$ Million) in Autologous Conditioned Plasma Therapy Business of Exactech, Inc. (2019-2024) Table 95. Exactech, Inc. Recent Developments Table 96. Plateltex S.R.O. Basic Information List Table 97. Plateltex S.R.O. Description and Business Overview Table 98. Plateltex S.R.O. Autologous Conditioned Plasma Therapy Products, Services and Solutions Table 99. Revenue (US$ Million) in Autologous Conditioned Plasma Therapy Business of Plateltex S.R.O. (2019-2024) Table 100. Plateltex S.R.O. Recent Developments Table 101. Key Raw Materials Lists Table 102. Raw Materials Key Suppliers Lists Table 103. Autologous Conditioned Plasma Therapy Downstream Customers Table 104. Autologous Conditioned Plasma Therapy Distributors List Table 105. Research Programs/Design for This Report Table 106. Key Data Information from Secondary Sources Table 107. Key Data Information from Primary Sources Table 108. Business Unit and Senior & Team Lead Analysts List of Figures Figure 1. Autologous Conditioned Plasma Therapy Product Picture Figure 2. Global Autologous Conditioned Plasma Therapy Sales Value, 2019 VS 2023 VS 2030 (US$ Million) Figure 3. Global Autologous Conditioned Plasma Therapy Sales Value (2019-2030) & (US$ Million) Figure 4. Autologous Conditioned Plasma Therapy Report Years Considered Figure 5. Global Autologous Conditioned Plasma Therapy Players Revenue Ranking (2023) & (US$ Million) Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Autologous Conditioned Plasma Therapy Revenue in 2023 Figure 7. Autologous Conditioned Plasma Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023 Figure 8. Pure Platelet-Rich Plasma (P-PRP) Picture Figure 9. Leukocyte- and Platelet-Rich Plasma (LPRP) Picture Figure 10. Pure Platelet-Rich Fibrin (P-PRF) Picture Figure 11. Leukocyte- and Platelet-Rich Fibrin (L-PRF) Picture Figure 12. Global Autologous Conditioned Plasma Therapy Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million) Figure 13. Global Autologous Conditioned Plasma Therapy Sales Value Market Share by Type, 2023 & 2030 Figure 14. Product Picture of Hospitals Figure 15. Product Picture of Specialized Clinics Figure 16. Product Picture of Ambulatory Surgical Centers Figure 17. Product Picture of Orthopedic & Trauma Centers Figure 18. Product Picture of Research Institutes Figure 19. Global Autologous Conditioned Plasma Therapy Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million) Figure 20. Global Autologous Conditioned Plasma Therapy Sales Value Market Share by Application, 2023 & 2030 Figure 21. North America Autologous Conditioned Plasma Therapy Sales Value (2019-2030) & (US$ Million) Figure 22. North America Autologous Conditioned Plasma Therapy Sales Value by Country (%), 2023 VS 2030 Figure 23. Europe Autologous Conditioned Plasma Therapy Sales Value (2019-2030) & (US$ Million) Figure 24. Europe Autologous Conditioned Plasma Therapy Sales Value by Country (%), 2023 VS 2030 Figure 25. Asia Pacific Autologous Conditioned Plasma Therapy Sales Value (2019-2030) & (US$ Million) Figure 26. Asia Pacific Autologous Conditioned Plasma Therapy Sales Value by Country (%), 2023 VS 2030 Figure 27. South America Autologous Conditioned Plasma Therapy Sales Value (2019-2030) & (US$ Million) Figure 28. South America Autologous Conditioned Plasma Therapy Sales Value by Country (%), 2023 VS 2030 Figure 29. Middle East & Africa Autologous Conditioned Plasma Therapy Sales Value (2019-2030) & (US$ Million) Figure 30. Middle East & Africa Autologous Conditioned Plasma Therapy Sales Value by Country (%), 2023 VS 2030 Figure 31. Key Countries/Regions Autologous Conditioned Plasma Therapy Sales Value (%), (2019-2030) Figure 32. United States Autologous Conditioned Plasma Therapy Sales Value, (2019-2030) & (US$ Million) Figure 33. United States Autologous Conditioned Plasma Therapy Sales Value by Type (%), 2023 VS 2030 Figure 34. United States Autologous Conditioned Plasma Therapy Sales Value by Application (%), 2023 VS 2030 Figure 35. Europe Autologous Conditioned Plasma Therapy Sales Value, (2019-2030) & (US$ Million) Figure 36. Europe Autologous Conditioned Plasma Therapy Sales Value by Type (%), 2023 VS 2030 Figure 37. Europe Autologous Conditioned Plasma Therapy Sales Value by Application (%), 2023 VS 2030 Figure 38. China Autologous Conditioned Plasma Therapy Sales Value, (2019-2030) & (US$ Million) Figure 39. China Autologous Conditioned Plasma Therapy Sales Value by Type (%), 2023 VS 2030 Figure 40. China Autologous Conditioned Plasma Therapy Sales Value by Application (%), 2023 VS 2030 Figure 41. Japan Autologous Conditioned Plasma Therapy Sales Value, (2019-2030) & (US$ Million) Figure 42. Japan Autologous Conditioned Plasma Therapy Sales Value by Type (%), 2023 VS 2030 Figure 43. Japan Autologous Conditioned Plasma Therapy Sales Value by Application (%), 2023 VS 2030 Figure 44. South Korea Autologous Conditioned Plasma Therapy Sales Value, (2019-2030) & (US$ Million) Figure 45. South Korea Autologous Conditioned Plasma Therapy Sales Value by Type (%), 2023 VS 2030 Figure 46. South Korea Autologous Conditioned Plasma Therapy Sales Value by Application (%), 2023 VS 2030 Figure 47. Southeast Asia Autologous Conditioned Plasma Therapy Sales Value, (2019-2030) & (US$ Million) Figure 48. Southeast Asia Autologous Conditioned Plasma Therapy Sales Value by Type (%), 2023 VS 2030 Figure 49. Southeast Asia Autologous Conditioned Plasma Therapy Sales Value by Application (%), 2023 VS 2030 Figure 50. India Autologous Conditioned Plasma Therapy Sales Value, (2019-2030) & (US$ Million) Figure 51. India Autologous Conditioned Plasma Therapy Sales Value by Type (%), 2023 VS 2030 Figure 52. India Autologous Conditioned Plasma Therapy Sales Value by Application (%), 2023 VS 2030 Figure 53. Autologous Conditioned Plasma Therapy Industrial Chain Figure 54. Autologous Conditioned Plasma Therapy Manufacturing Cost Structure Figure 55. Channels of Distribution (Direct Sales, and Distribution) Figure 56. Bottom-up and Top-down Approaches for This Report Figure 57. Data Triangulation
